Table 1. Prognostic clinicopathological variables as predictors for disease-specific survival in 249 non-GIST STSs (univariate analyses, log-rank test).

Characteristic	Patients(n)	Patients(%)	Median survival(months)	5-Year survival(%)	P
Age
≤ 20 years	20	8	15	40	0.126
21–60 years	113	45	68	52
>60 years	116	47	30	40
Gender
Male	110	44	41	46	0.390
Female	139	56	45	45
Patient nationality
Norwegian	167	67	63	51	0.011
Russian	82	33	22	34
Histological entity
Pleomorphic sarcoma	68	27	29	40	0.102
Leiomyosarcoma	67	27	45	46
Liposarcoma	34	14	NR	67
MF/MFT	20	8	43	50
Angiosarcoma	13	5	10	31
Rhabdomyosarcoma	16	6	17	38
MPNST	11	5	49	45
Synovial sarcoma	16	6	31	29
Other STSs	4	2	NR	18
Tumor localization
Extremities	89	36	100	53	0.348
Trunk	47	29	32	44
Retroperitoneum	37	25	25	38
Head/Neck	18	7	15	41
Visceral	58	23	30	42
Tumor size
≤ 5 cm	74	30	127	57	0.027
5–10 cm	91	37	44	45
>10 cm	81	32	28	36
Missing	3	1
Malignancy grade
1	61	25	NR	74	<0.001
2	98	39	41	45
3	90	36	16	26
Tumor depth
Superficial	17	7	NR	93	<0.001
Deep	232	93	36	42
Metastasis at time of diagnosis
No	206	83	76	53	<0.001
Yes	43	17	10	10
Surgery
Yes	228	92	59	50	<0.001
No	21	8	5	0
Resection margins
Free	178	71	127	66	<0.001
Not free/no surgery	71	29	10	18
Chemotherapy
No	191	77	52	47	0.424
Yes	58	23	29	40
Radiotherapy
No	176	71	48	46	0.590
Yes	73	29	38	43

Abbreviations: NR, not reached; MF/MFT, malignant fibroblastic/myofibroblastic tumors; MPNST, malignant peripheral nerve sheath tumor; NOS, not otherwise specified; non-GIST STS, non-gastro intestinal stromal tumor soft-tissue sarcoma.